Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.4% Following Insider Selling

Gyre Therapeutics, Inc. (NASDAQ:GYREGet Free Report)’s share price was down 4.4% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $12.10 and last traded at $12.10. Approximately 38,531 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 75,509 shares. The stock had previously closed at $12.66.

Specifically, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the sale, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Gyre Therapeutics Stock Down 4.4 %

The company’s fifty day moving average is $12.64 and its two-hundred day moving average is $12.67.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares in the last quarter. Geode Capital Management LLC raised its holdings in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after acquiring an additional 43,840 shares in the last quarter. State Street Corp increased its holdings in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares during the last quarter. FMR LLC bought a new position in Gyre Therapeutics during the third quarter worth about $47,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics during the 3rd quarter valued at $334,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

See Also

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.